# US 2024/0199678 A1 · MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199678 A1
- Document ID: US20240199678A1
- Status: Published application
- Kind: A1
- Application number: 18/354,860
- Filed: 2023-07-19
- Published: 2024-06-20
- Earliest claimed: 2017-09-21
- Assignees: Chimerix, Inc.
- Applicants: Chimerix, Inc.
- Inventors: Roy W. WARE, JR.; Venkat LAKSHMANAN; Aaron Leigh DOWNEY
- Web page: https://patentgrep.com/patent/US20240199678A1

## CPC

- C07D 487/04: Ortho-condensed systems
- C07H 19/14: Pyrrolo-pyrimidine radicals
- A61P 31/12: Antivirals
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to crystalline morphic forms of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide. The morphic form can be a stable hemihydrate crystalline form.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A crystalline Form (“Form B”) of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, wherein the Form has a powder X-ray diffraction pattern comprising a peak at a diffraction angle (2θ) of about 22.9, wherein said powder X-ray diffraction pattern is obtained using Cu Kα1 X-rays at a wavelength of 1.5406 Å.

### Claim at position 3

19-25. (canceled)

### Claim 26

A method of treating a viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a crystalline form of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide.

### Claim 27 (depends on 26)

The method of claim 26, wherein the crystalline form is a crystalline hemihydrate form.

### Claim 28 (depends on 26)

The method of claim 26, wherein the viral infection is selected from norovirus, human cytomegalovirus, BK virus, Epstein-Barr virus, adenovirus, JC virus, SV40, MC virus, KI virus, WU virus, vaccinia, herpes simplex virus 1, herpes simplex virus 2, human herpes virus 6, human herpes virus 8, hepatitis B virus, hepatitis C virus, varicella zoster virus, variola major, variola minor, smallpox, cowpox, camelpox, monkeypox, poliovirus, picornaviridae, paramyxoviridae, ebola virus, Marburg virus, influenza, enterovirus, papilloma virus, West Nile virus, yellow fever virus, foot-and-mouth disease virus, Rift Valley fever virus, and other flavivirus, arenavirus, bunyavirus, alphavirus, human immunodeficiency virus, and any combination thereof.

### Claim at position 7

-32. (canceled)

### Claim 33

A method of preparing a crystalline hemihydrate form of 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide comprising:
recrystallizing the 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide from a solvent system comprising 1-propanol and 0.01 M aqueous NaOH.

### Claim 34 (depends on 33)

The method of claim 33, wherein the solvent system comprises 1-propanol and 0.01 M aqueous NaOH at a volume ratio of 1:2.

### Claim 35 (depends on 33)

The method of claim 33, wherein the 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide is dissolved in the solvent system comprising 1-propanol and 0.01 M aqueous NaOH at a temperature of about 90° C. to produce a solution.

### Claim 36 (depends on 35)

The method of claim 35, wherein the solution is cooled to about 80° C. and stirred for about an hour.

### Claim 37 (depends on 3, 35)

The method of claim 35, wherein the solution is seeded with the morphic form of claim 3.

### Claim 38 (depends on 37)

The method of claim 37, wherein the seed comprises about 1% of the amount of Compound 1 in the solution.

### Claim 39 (depends on 36)

The method of claim 36, wherein the solution is further cooled to a temperature of about 5° C.

### Claim 40 (depends on 39)

The method of claim 39, wherein the solution is stirred at about 5° C. for about 4 hours.

### Claim 41 (depends on 39)

The method of claim 39, wherein the cooling rate is about 5K/hour.

### Claim 42 (depends on 33)

The method of claim 33, wherein the crystallized 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide is further washed with water.

### Claim 43 (depends on 33)

The method of claim 33, wherein the crystallized 4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide is over 99% pure.
